Highlights Acelyrin, Inc.

Equities

SLRN

US00445A1007

Real-time Estimate Cboe BZX Other stock markets 12:28:27 2024-06-05 pm EDT			5-day change	1st Jan Change
4.265 ^USD	+0.12%		+4.90%	-42.63%

01:00pm	ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024	CI
May. 22	HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024	07:00am	CI
Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Acelyrin, Inc. Announces CEO Changes	May. 09	CI
Acelyrin, Inc. Announces Leadership Transition	May. 09	CI
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care	Mar. 20	MT
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial	Mar. 20	MT
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	Mar. 20	CI
Acelyrin, Inc. Announces Positive Top-Line Results from Its Global Phase 2B/3 Clinical Trial of Izokibep in Psoriatic Arthritis	Mar. 11	CI
Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa	Mar. 11	CI
ACELYRIN Flags 'Clinical Execution Errors' in Hidradenitis Suppurativa Trials Involving Contract Research Organization	Nov. 28	MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
ACELYRIN Flags 'Clinical Execution Errors' in Hidradenitis Suppurativa Trials Involving Contract Research Organization	Nov. 27	MT
Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program	Nov. 27	CI
Acelyrin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Acelyrin Shares Plunge After Izokibep Trial Misses Primary Endpoint	23-09-12	MT
Acelyrin tumbles after skin disease drug fails key trial	23-09-12	RE
Acelyrin Results From Izokibep Trial for Hidradenitis Suppurativa Fail to Meet Primary Endpoint; Shares Sink Premarket	23-09-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Acelyrin, Inc.

Equities

SLRN

US00445A1007

Highlights

Filters